822 related articles for article (PubMed ID: 20492521)
21. Treatment of cirrhotic ascites.
Schouten J; Michielsen PP
Acta Gastroenterol Belg; 2007; 70(2):217-22. PubMed ID: 17715638
[TBL] [Abstract][Full Text] [Related]
22. Cirrhotic ascites: pathogenesis and management.
Garcia-Tsao G
Gastroenterologist; 1995 Mar; 3(1):41-54. PubMed ID: 7743121
[TBL] [Abstract][Full Text] [Related]
23. Pathophysiology, diagnosis and treatment of ascites in cirrhosis.
Uriz J; Cárdenas A; Arroyo V
Baillieres Best Pract Res Clin Gastroenterol; 2000 Dec; 14(6):927-43. PubMed ID: 11139347
[TBL] [Abstract][Full Text] [Related]
24. Randomized controlled study of TIPS versus paracentesis plus albumin in cirrhosis with severe ascites.
Salerno F; Merli M; Riggio O; Cazzaniga M; Valeriano V; Pozzi M; Nicolini A; Salvatori F
Hepatology; 2004 Sep; 40(3):629-35. PubMed ID: 15349901
[TBL] [Abstract][Full Text] [Related]
25. Management of ascites in patients with end-stage liver disease.
Saadeh S; Davis GL
Rev Gastroenterol Disord; 2004; 4(4):175-85. PubMed ID: 15580152
[TBL] [Abstract][Full Text] [Related]
26. [Transjugular intrahepatic portosystemic stent-shunts or paracentesis in the treatment of cirrhotic patients with refractory ascites].
Ainsworth MA; Nielsen OH
Ugeskr Laeger; 2005 Aug; 167(35):3273-6. PubMed ID: 16138966
[No Abstract] [Full Text] [Related]
27. Hepatorenal syndrome.
Bataller R; Ginès P; Guevara M; Arroyo V
Semin Liver Dis; 1997; 17(3):233-47. PubMed ID: 9308128
[TBL] [Abstract][Full Text] [Related]
28. Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome.
Wong F; Pantea L; Sniderman K
Hepatology; 2004 Jul; 40(1):55-64. PubMed ID: 15239086
[TBL] [Abstract][Full Text] [Related]
29. Hepatorenal syndrome and ascites--an introduction.
Gentilini P
Liver; 1999; 19(1 Suppl):5-14. PubMed ID: 10226999
[No Abstract] [Full Text] [Related]
30. Transjugular intrahepatic portosystemic shunt and alfapump® system for refractory ascites in liver cirrhosis: Outcomes and complications.
Will V; Rodrigues SG; Stirnimann G; Gottardi A; Bosch J; Berzigotti A
United European Gastroenterol J; 2020 Oct; 8(8):961-969. PubMed ID: 32588789
[TBL] [Abstract][Full Text] [Related]
31. [Current ascites therapy].
Ochs A
Praxis (Bern 1994); 1997 Jan; 86(4):94-7. PubMed ID: 9064726
[TBL] [Abstract][Full Text] [Related]
32. TIPS for the treatment of refractory ascites, hepatorenal syndrome and hepatic hydrothorax: a critical update.
Rössle M; Gerbes AL
Gut; 2010 Jul; 59(7):988-1000. PubMed ID: 20581246
[TBL] [Abstract][Full Text] [Related]
33. [Transjugular intrahepatic portosystemic shunt in the treatment of refractory ascites in 21 patients].
Vandistel G; Nevens F; Stockx L; Raat H; Wilms G; Fevery J
Ned Tijdschr Geneeskd; 1996 Dec; 140(49):2455-8. PubMed ID: 8999346
[TBL] [Abstract][Full Text] [Related]
34. Transjugular intrahepatic portal-systemic shunt in the treatment of refractory ascites: effect on clinical, renal, humoral, and hemodynamic parameters.
Quiroga J; Sangro B; Núñez M; Bilbao I; Longo J; García-Villarreal L; Zozaya JM; Betés M; Herrero JI; Prieto J
Hepatology; 1995 Apr; 21(4):986-94. PubMed ID: 7705810
[TBL] [Abstract][Full Text] [Related]
35. Management of cirrhosis and ascites.
Ginès P; Cárdenas A; Arroyo V; Rodés J
N Engl J Med; 2004 Apr; 350(16):1646-54. PubMed ID: 15084697
[No Abstract] [Full Text] [Related]
36. Management of refractory ascites.
Singhal S; Baikati KK; Jabbour II; Anand S
Am J Ther; 2012 Mar; 19(2):121-32. PubMed ID: 21192246
[TBL] [Abstract][Full Text] [Related]
37. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis.
European Association for the Study of the Liver
J Hepatol; 2010 Sep; 53(3):397-417. PubMed ID: 20633946
[No Abstract] [Full Text] [Related]
38. Ascites in cirrhosis: a review of management and complications.
Kuiper JJ; van Buuren HR; de Man RA
Neth J Med; 2007 Sep; 65(8):283-8. PubMed ID: 17890787
[TBL] [Abstract][Full Text] [Related]
39. Midodrine and octreotide in treatment of cirrhosis-related hemodynamic complications.
Karwa R; Woodis CB
Ann Pharmacother; 2009 Apr; 43(4):692-9. PubMed ID: 19299324
[TBL] [Abstract][Full Text] [Related]
40. [New therapeutic paradigm and concepts for patients with cirrhotic refractory ascites].
Wang SZ; Ding HG
Zhonghua Gan Zang Bing Za Zhi; 2017 Apr; 25(4):249-253. PubMed ID: 28494541
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
